185 related articles for article (PubMed ID: 35740624)
1. Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma
Davidi S; Jacobovitch S; Shteingauz A; Martinez-Conde A; Braten O; Tempel-Brami C; Zeevi E; Frechtel-Gerzi R; Ene H; Dor-On E; Voloshin T; Tzchori I; Haber A; Giladi M; Kinzel A; Weinberg U; Palti Y
Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740624
[TBL] [Abstract][Full Text] [Related]
2. Tumor-treating fields in combination with sorafenib restrain the proliferation of liver cancer
Jang Y; Lee WS; Sai S; Kim JY; Kim JK; Kim EH
Oncol Lett; 2022 Oct; 24(4):338. PubMed ID: 36039063
[TBL] [Abstract][Full Text] [Related]
3. Tumor Treating Fields Concomitant with Sorafenib in Advanced Hepatocellular Cancer: Results of the HEPANOVA Phase II Study.
Gkika E; Grosu AL; Macarulla Mercade T; Cubillo Gracián A; Brunner TB; Schultheiß M; Pazgan-Simon M; Seufferlein T; Touchefeu Y
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326718
[TBL] [Abstract][Full Text] [Related]
4. Functional Biological Activity of Sorafenib as a Tumor-Treating Field Sensitizer for Glioblastoma Therapy.
Jo Y; Kim EH; Sai S; Kim JS; Cho JM; Kim H; Baek JH; Kim JY; Hwang SG; Yoon M
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30469352
[TBL] [Abstract][Full Text] [Related]
5. Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy.
Voloshin T; Kaynan N; Davidi S; Porat Y; Shteingauz A; Schneiderman RS; Zeevi E; Munster M; Blat R; Tempel Brami C; Cahal S; Itzhaki A; Giladi M; Kirson ED; Weinberg U; Kinzel A; Palti Y
Cancer Immunol Immunother; 2020 Jul; 69(7):1191-1204. PubMed ID: 32144446
[TBL] [Abstract][Full Text] [Related]
6. Tumor Treating Fields (TTFields) downregulate the Fanconi Anemia-BRCA pathway and increase the efficacy of chemotherapy in malignant pleural mesothelioma preclinical models.
Mumblat H; Martinez-Conde A; Braten O; Munster M; Dor-On E; Schneiderman RS; Porat Y; Voloshin T; Davidi S; Blatt R; Shteingauz A; Tempel-Brami C; Zeevi E; Lajterer C; Shmueli Y; Danilov S; Haber A; Giladi M; Weinberg U; Kinzel A; Palti Y
Lung Cancer; 2021 Oct; 160():99-110. PubMed ID: 34482104
[TBL] [Abstract][Full Text] [Related]
7. Tumor-treating fields in combination with sorafenib curtails the growth of colorectal carcinoma by inactivating AKT/STAT3 signaling.
Kim EH; Lee WS; Oh HK
Transl Cancer Res; 2022 Aug; 11(8):2553-2561. PubMed ID: 36093532
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib increases tumor treating fields-induced cell death in glioblastoma by inhibiting STAT3.
Kim JY; Jo Y; Oh HK; Kim EH
Am J Cancer Res; 2020; 10(10):3475-3486. PubMed ID: 33163284
[TBL] [Abstract][Full Text] [Related]
9. Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis.
Shi YH; Ding ZB; Zhou J; Hui B; Shi GM; Ke AW; Wang XY; Dai Z; Peng YF; Gu CY; Qiu SJ; Fan J
Autophagy; 2011 Oct; 7(10):1159-72. PubMed ID: 21691147
[TBL] [Abstract][Full Text] [Related]
10. Tumor Treating Fields (TTFields) Concomitant with Immune Checkpoint Inhibitors Are Therapeutically Effective in Non-Small Cell Lung Cancer (NSCLC) In Vivo Model.
Barsheshet Y; Voloshin T; Brant B; Cohen G; Koren L; Blatt R; Cahal S; Haj Khalil T; Zemer Tov E; Paz R; Klein-Goldberg A; Tempel-Brami C; Jacobovitch S; Volodin A; Kan T; Koltun B; David C; Haber A; Giladi M; Weinberg U; Palti Y
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430552
[TBL] [Abstract][Full Text] [Related]
11. Alternating electric fields (tumor-treating fields therapy) can improve chemotherapy treatment efficacy in non-small cell lung cancer both in vitro and in vivo.
Giladi M; Weinberg U; Schneiderman RS; Porat Y; Munster M; Voloshin T; Blatt R; Cahal S; Itzhaki A; Onn A; Kirson ED; Palti Y
Semin Oncol; 2014 Oct; 41 Suppl 6():S35-41. PubMed ID: 25213867
[TBL] [Abstract][Full Text] [Related]
12. The schemes, mechanisms and molecular pathway changes of Tumor Treating Fields (TTFields) alone or in combination with radiotherapy and chemotherapy.
Tanzhu G; Chen L; Xiao G; Shi W; Peng H; Chen D; Zhou R
Cell Death Discov; 2022 Oct; 8(1):416. PubMed ID: 36220835
[TBL] [Abstract][Full Text] [Related]
13. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
Wang L; Zhan Y; Wu Z; Lin M; Jin X; Jiang L; Qiu Y
Biomed Pharmacother; 2020 May; 125():110033. PubMed ID: 32187962
[TBL] [Abstract][Full Text] [Related]
14. Mitotic disruption and reduced clonogenicity of pancreatic cancer cells in vitro and in vivo by tumor treating fields.
Giladi M; Schneiderman RS; Porat Y; Munster M; Itzhaki A; Mordechovich D; Cahal S; Kirson ED; Weinberg U; Palti Y
Pancreatology; 2014; 14(1):54-63. PubMed ID: 24555979
[TBL] [Abstract][Full Text] [Related]
15. Can tumor treating fields induce DNA damage and reduce cell motility in medulloblastoma cell lines?
Nitta RT; Luo EJ; Lim M; Li G
J Neurosurg Pediatr; 2022 Dec; 30(6):555-566. PubMed ID: 36208441
[TBL] [Abstract][Full Text] [Related]
16. Cholesterol sensor SCAP contributes to sorafenib resistance by regulating autophagy in hepatocellular carcinoma.
Li D; Yao Y; Rao Y; Huang X; Wei L; You Z; Zheng G; Hou X; Su Y; Varghese Z; Moorhead JF; Chen Y; Ruan XZ
J Exp Clin Cancer Res; 2022 Mar; 41(1):116. PubMed ID: 35354475
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma.
Zhai B; Hu F; Jiang X; Xu J; Zhao D; Liu B; Pan S; Dong X; Tan G; Wei Z; Qiao H; Jiang H; Sun X
Mol Cancer Ther; 2014 Jun; 13(6):1589-98. PubMed ID: 24705351
[TBL] [Abstract][Full Text] [Related]
18. Melatonin Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib through the PERK-ATF4-Beclin1 Pathway.
Zhou B; Lu Q; Liu J; Fan L; Wang Y; Wei W; Wang H; Sun G
Int J Biol Sci; 2019; 15(9):1905-1920. PubMed ID: 31523192
[TBL] [Abstract][Full Text] [Related]
19. Tumor Treating Fields (TTFields) Therapy Concomitant with Taxanes for Cancer Treatment.
Vergote I; Macarulla T; Hirsch FR; Hagemann C; Miller DS
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765594
[TBL] [Abstract][Full Text] [Related]
20. ADRB2 signaling promotes HCC progression and sorafenib resistance by inhibiting autophagic degradation of HIF1α.
Wu FQ; Fang T; Yu LX; Lv GS; Lv HW; Liang D; Li T; Wang CZ; Tan YX; Ding J; Chen Y; Tang L; Guo LN; Tang SH; Yang W; Wang HY
J Hepatol; 2016 Aug; 65(2):314-24. PubMed ID: 27154061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]